Navigation Links
HIV Patients Opposes Patenting Of AIDS Drug

An Indian group of people living with HIV/AIDS have opposed a patent application filed by global pharma major GlaxoSmithKline for Combivir, a fixed dose combination AIDS drug on the grounds that it would make the treatment unaffordable. //

Represented by the Lawyers' Collective HIV/AIDS Unit, the Indian Network of People Living with HIV/AIDS and the Manipur Network of Positive People Thursday officially submitted their opposition to a patent application filed at the Kolkata patent office by GlaxoSmithKline.

The opposition is based on technical and health grounds.

'We are objecting to the patenting of Combivir - a fixed-dose combination of the two essential AIDS drugs zidovudine and lamivudine - because it is not a new invention but simply the combination of two existing drugs,' said K.K. Abraham, president of the Indian Network of People Living with HIV/AIDS.

'More importantly, the granting of such a patent risks increasing the cost of anti-retroviral treatment for many people living with HIV/AIDS, thereby further increasing the burden on developing countries already struggling to treat patients.'

Combivir is used extensively in projects run by international aid organisations such as Medecins Sans Frontieres (MSF). Almost all the Combivir used by MSF is generic.

India, Burkina Faso, Mongolia, Central African Republic, Malawi, Peru, Kyrgyzstan, Cambodia, Ukraine and Swaziland are other countries identified by the Global Fund for using generic Combivir.

'Decisions made by Indian patent offices are a question of life or death for people living with HIV/AIDS who rely on the availability of affordable AIDS drugs and other essential medicines made by Indian generic manufacturers,' said Anand Grover, director of Lawyers Collective HIV/AIDS Unit.

Last year, India changed its patent law to comply with the World Trade Organisation's TRIPS Agreement that governs trade pacts and in tellectual property rights.

Three weeks ago, India granted its first patent on a drug to a Hepatitis C treatment produced by Roche.

Public interest groups are deeply concerned that this will set a precedent, leading to the patenting of other essential medicines including anti-retrovirals for treatment of HIV/AIDS.

--Edited IANS

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patients often assume wrongly that they are allergic to penicillin
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. Hemochromatosis Patients Blood is Safe
9. Patients Pressure Would Result In Overprescription
10. Risk Of Decongestants In Hypertensive Patients
11. Interference helps Heart Patients
Post Your Comments:

(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to ... Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored ... one of twelve colleges and universities in the state of California make the cut. ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients ... central Michigan, have come together on Thanksgiving Day to share the things that ... viewing on the Serenity Point YouTube channel, patients displayed what they wrote on ...
(Date:11/26/2015)... ... ... Jobs in hospital medical laboratories and in the imaging field lead the ... Aureus Medical Group . These fields, as well as travel nursing, ranked ... jobs through the company’s website, , The leading healthcare staffing agency ...
(Date:11/26/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact center ... reliability. , The new Q-Suite 6 platform is based on the latest Java Enterprise ... a specific piece of software for many key components of the suite. Much of ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... recognized once again for its stellar workplace culture with the company’s Cincinnati office ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati Business Courier’s ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 27, 2015 /PRNewswire/ ... --> Medical ... response system (PERS) market is ... 5 years with APAC being ... to see a high CAGR ...
(Date:11/26/2015)... --> --> ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... with Bremachlorin-photodynamic therapy for advanced cancer.   ... with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy can be efficiently combined with photodynamic therapy (PDT) ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and Markets ( ... Pacific Cardiac Pacemaker Market Outlook to 2019 - Rise in ... Demand " report to their offering. ... Boston scientific and others. ... including Medtronic, Biotronik, Boston scientific and ...
Breaking Medicine Technology: